Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMMA - Medico Economic Evaluation of Fluocinolone Acetonide Implant Versus Dexamethasone Implant in Resistant Diabetic Macular Oedema
2024-513983-24-00Phase 4Authorised
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Jul 2024
- Modality
- Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial in diabetic macular edema (DME) comparing Iluvien arm with Ozurdex arm (2 arms). Primary endpoint: Incremental cost-utility ratio at 3 years. Planned start Jul 2024; status: authorised.
02
Drugs
fluocinoloneozurdex
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2024-513983-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513983-24-00.